BAGNEUX, France, Feb. 18, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, and the Icahn School of Medicine at Mount Sinai announced today that they entered into a research collaboration agreement to investigate the efficacy and mechanism of epicutaneous tolerance utilizing Viaskin® for the treatment of Crohn's disease. Crohn's disease is a chronic condition for which there is currently no satisfactory cure able to increase the quality of life for people who have Crohn's disease. DBV has already proven, in several pre-clinical studies that repeated epicutaneous immunotherapy (EPIT TM ) leads to increase natural and induced immune regulatory cells. Preliminary studies already showed that these immune regulatory cells play an essential role in by protecting the gut from inflammation. DBV partnered with the Mount Sinai team, which has world-class expertise in cellular mechanisms involved in Crohn's disease, having already demonstrated that administration of Tregs to patients with severe Crohn's disease was well tolerated and efficacious. DBV has established that Induction of immune regulatory cells can be achieved by epicutaneous exposure. The combination of DBV's technology with Mount Sinai's expertise could lead to a first-in-class approach to induce tolerance and decrease gut inflammation. Pr. Jean-Frédéric Colombel , Director of The Leona M. and Harry B. Helmsley Charitable Trust Inflammatory Bowel Disease Center at Mount Sinai Hospital (New-York, NY, USA), said, " We are very excited with this collaboration. There is still a huge unmet need in the treatment of Crohn's disease. This new technology could offer to our patients' new opportunities and pave the way for an original approach aiming at amplifying the effect of immune regulatory cells instead of targeting immune suppression and its associated potential side effects". Dr. David Dunkin , Assistant Professor of Pediatrics in the Division of Pediatric Gastroenterology The Icahn School of Medicine at Mount Sinai (New-York, NY, USA), said, " This collaboration is exciting because it develops a new possibility for a treatment for Crohn's disease by utilizing a patient's normal immune response to treat disease. Through the technology at DBV and the scientific expertise at both institutions working in collaboration we hope to one day offer our patients a new safe therapy for the treatment of Crohn's disease" Dr. Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies, said, " Mount Sinai is a leading center in gastroenterology worldwide, at the forefront of Crohn's disease research initiatives. We are extremely proud to contribute, along with Pr. Colombel and Dr. Dunkin, to a novel approach using Viaskin® in a severe condition, with no therapeutic alternative. We believe this new research area with such a center of excellence further emphasizes the potential of the Viaskin platform, positioning it as a technology enabling a deep and durable modulation of the immune system." The Collaboration will explore a novel approach to treat Crohn's disease based on epicutaneous delivery with Viaskin® to induce regulatory cells (Treg). Pre-clinical studies will aim at:
- Evaluating the ability of epicutaneous tolerance induction with Viaskin® to treat inflammatory colitis
- Demonstrating the functional ability of antigen-specific Tregs induced by epicutaneous exposure with Viaskin® in suppressing inflammatory responses in the gut,
- Acquiring a better knowledge of cellular mechanisms involved.